Searchable abstracts of presentations at key conferences in endocrinology

ea0015p311 | Steroids | SFEBES2008

Testosterone increases kidney weight in orchiectomized male Wistar rats but not dihydrotestosterone

Michaelis Marten , Hofmann Peter , Rohde Wolfgang , Goetze Franziska , Quinkler Marcus

Introduction: Androgens are known to play an important role in renal tubular epithelial cell growth, hypertrophy and erythropoetin production, however the exact mechanisms are not clear yet. 5α-dihydrotestosterone is synthesized primarily in gonads and skin, and is the most used androgen in studies. However, little is known about testosterone effects in non-gonadal tissues.Methods: Male Wistar rats aged 8–10 weeks were orchiectomized and put on...

ea0013p51 | Clinical practice/governance and case reports | SFEBES2007

Medical treatment in adrenal insufficiency: Does the patient’s quality of life differ depending on which glucocorticoid is given?

Bleicken Benjamin , Ventz Manfred , Strasburger Christian J , Quinkler Marcus

Objective: Patients from FRG and West-Berlin with primary (1AI) or secondary (2AI) adrenal insufficiency were treated with hydrocortisone (HC) while in contrast patients from the former GDR received prednisolone (PR). Investigation of our study is to detect any differences in quality of life (QoL) in patients on HC or PR medication.Methods: 350 patients of our outpatient clinic were contacted by mail. Up to now 131 patients took part in the survey. 2 sta...

ea0090oc9.4 | Oral Communications 9: Adrenal and Cardiovascular Endocrinology 2 | ECE2023

Recovery of adrenal function after stopping mitotane in patients with adrenocortical carcinoma

Altieri Barbara , Kimpel Otilia , Megerle Felix , Detomas Mario , Chifu Irina , Quinkler Marcus , Matthias Kroiss , Fassnacht Martin

Background: Mitotane is regularly used in patients with adrenocortical carcinoma (ACC) adjuvantly, in patients with high risk of recurrence, and in advanced disease. Multiple effects of mitotane result in adrenal insufficiency in virtually all patients. However, it is unclear how frequently the hypothalamic-pituitary-adrenal (HPA) axis is recovering after treatment discontinuation. Here, we aim to investigate the HPA axis after treatment with mitotane.Me...

ea0090rc9.3 | Rapid Communications 9: Adrenal and Cardiovascular Endocrinology 2 | ECE2023

Fingerprints of increased susceptibility to adrenal crises in patients with chronic adrenal insufficiency

Chifu Irina , Janik Freytag , Quinkler Marcus , Herterich Sabine , Stephanie Burger-Stritt , Hahner Stefanie

Background: Potentially fatal adrenal crises (AC) still occur in educated patients with adrenal insufficiency (AI). Identifying predisposing factors is necessary for prevention in this patient population.Objectives: Investigating clinical and biochemical fingerprints of increased susceptibility to AC.Material and methods: Our study population included 260 patients with chronic AI, classified as high and low risk according to the fr...

ea0049gp11 | Adrenal 2 | ECE2017

A country comparison of glucocorticoid replacement therapy in patients with primary and secondary adrenal insufficiency: data from the EU-AIR

Ekman Bertil , Quinkler Marcus , Zhang Pinggao , Zelissen Pierre , Murray Robert D.

Introduction: The daily maintenance dose of conventional hydrocortisone currently recommended by international guidelines for the management of primary adrenal insufficiency (PAI) or secondary adrenal insufficiency (SAI) is 15−25 mg/day, in 2−3 divided doses. The aim of this analysis was to investigate inter-country differences in glucocorticoid replacement doses in patients with PAI and SAI.Design: EU-AIR (ClinicalTrials.gov identifier: NCT0...

ea0049gp20 | Adrenal 2 | ECE2017

Which are the factors and causes of death in patients with adrenal insufficiency? Mortality data from EU-AIR

Quinkler Marcus , Ekman Bertil , Zhang Pinggao , Zelissen Pierre , Murray Robert D

Introduction: If untreated, adrenal insufficiency (AI) leads to premature death. Hospital record data suggest mortality associated with primary (PAI) and secondary AI (SAI) to be 2–3-fold higher than in the general population. Major causes of death include cardiovascular disease, Addisonian crises, brain tumours and infections; however, there is little further characterization of patients who died.Design: We analysed real-world data from the Europea...

ea0049ep22 | Adrenal cortex (to include Cushing's) | ECE2017

Cardiovascular risk factors do not play a role in the risk factor profile of adrenal crisis

Quinkler Marcus , Murray Robert D. , Zhang Pinggao , Zelissen Pierre , Ekman Bertil

Introduction: Adrenal crises (ACs) are life-threatening events in patients with primary (PAI) or secondary (SAI) adrenal insufficiency, occurring ~4–10 times per 100 patient-years. Major causes of ACs are infections, especially gastroenteritis and tonsillitis/laryngitis. Risk factors for ACs remain ill defined, but could include concomitant endocrine diseases (diabetes mellitus, premature ovarian failure) in PAI, diabetes insipidus in SAI, and concomitant non-endocrine di...

ea0041oc1.3 | Adrenal - Basic & Clinical | ECE2016

Hormone replacement therapy with prednisolone is associated with a worse lipid profile than replacement with hydrocortisone in patients with adrenal insufficiency: a matched analysis of data from the EU-AIR

Quinkler Marcus , Ekman Bertil , Marelli Claudio , Uddin Sharif , Zelissen Pierre , Murray Robert

Introduction: Prednisolone is the standard treatment for most inflammatory conditions. However, it is also used in hormone replacement therapy in adrenal insufficiency (AI) for historical reasons or due to its longer half-life and once-daily application. Recent data indicate that daily prednisolone could be associated with lower bone mineral density than daily hydrocortisone in patients with AI. However, data on risk factors for cardiovascular disease in patients with AI treat...

ea0038p410 | Steroids | SFEBES2015

Hormone replacement therapy with prednisolone in adrenal insufficiency patients: data from the European Adrenal Insufficiency Registry (EuAIR)

Quinkler Marcus , Ekman Bertil , Marelli Claudio , Uddin Sharif , Zelissen Pierre , Murray Robert

Introduction: Prednisolone is the standard treatment for most inflammatory conditions. However, it is also used in hormone replacement therapy in adrenal insufficiency (AI) due to historical reasons or due to its longer half-life and once daily application. Recent data showed that 5 mg daily prednisolone promotes loss in bone mineral density compared to 20 mg of hydrocortisone in patients with AI questioning the 4:1 conversion rate. Data is scarce on prednisolone treated AI pa...